John Zygiel, MD

For patients with gastroesophageal reflux disease (GERD) who take proton pump inhibitors (PPIs) more than once daily, an attempt to reduce dosing to once daily will be successful in over 80%, with little change in quality of life.

Given the expense of these medications, clinicians should undertake a trial of once-daily dosing for patients on higher doses, after their initial symptoms are controlled for at least 8 weeks. Though dose reduction is harder to achieve when patients have been taking a PPI long-term, 84% of such patients who could not tolerate an initial dose reduction were able to do so on a subsequent attempt.

For patients with gastroesophageal reflux disease (GERD) who take proton pump inhibitors (PPIs) more than once daily, an attempt to reduce dosing to once daily will be successful in over 80%, with little change in quality of life.

Given the expense of these medications, clinicians should undertake a trial of once-daily dosing for patients on higher doses, after their initial symptoms are controlled for at least 8 weeks. Though dose reduction is harder to achieve when patients have been taking a PPI long-term, 84% of such patients who could not tolerate an initial dose reduction were able to do so on a subsequent attempt.

For patients with gastroesophageal reflux disease (GERD) who take proton pump inhibitors (PPIs) more than once daily, an attempt to reduce dosing to once daily will be successful in over 80%, with little change in quality of life.

Given the expense of these medications, clinicians should undertake a trial of once-daily dosing for patients on higher doses, after their initial symptoms are controlled for at least 8 weeks. Though dose reduction is harder to achieve when patients have been taking a PPI long-term, 84% of such patients who could not tolerate an initial dose reduction were able to do so on a subsequent attempt.